Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission REVIEW Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials John Koreth, MBBS, DPhil Context The optimal treatment of acute myeloid leukemia (AML) in first complete Richard Schlenk, MD remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recom- mends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not Kenneth J. Kopecky, PhD for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation che- Sumihisa Honda, PhD motherapy are considered of equivalent benefit for intermediate-risk AML. Jorge Sierra, MD, PhD Objective To quantify relapse-free survival (RFS) and overall survival benefit of allo- geneic SCT for AML in CR1 overall and also for good-, intermediate-, and poor-risk AML. Benjamin J. Djulbegovic, MD, PhD Methods Systematic review and meta-analysis of prospective trials evaluating allo- Martha Wadleigh, MD geneic SCT vs nonallogeneic SCT therapies for AML in CR1. The search used the com- Daniel J. DeAngelo, MD, PhD bined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/ Richard M. Stone, MD aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009. The search identified 1712 articles. Hisashi Sakamaki, MD, PhD Study Selection Prospective trials http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

Download PDF
13 pages

Loading next page...
 
/lp/american-medical-association/allogeneic-stem-cell-transplantation-for-acute-myeloid-leukemia-in-PEvoJTbM5q

References (50)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.813
pmid
19509382
Publisher site
See Article on Publisher Site

Abstract

REVIEW Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials John Koreth, MBBS, DPhil Context The optimal treatment of acute myeloid leukemia (AML) in first complete Richard Schlenk, MD remission (CR1) is uncertain. Current consensus, based on cytogenetic risk, recom- mends myeloablative allogeneic stem cell transplantation (SCT) for poor-risk but not Kenneth J. Kopecky, PhD for good-risk AML. Allogeneic SCT, autologous transplantation, and consolidation che- Sumihisa Honda, PhD motherapy are considered of equivalent benefit for intermediate-risk AML. Jorge Sierra, MD, PhD Objective To quantify relapse-free survival (RFS) and overall survival benefit of allo- geneic SCT for AML in CR1 overall and also for good-, intermediate-, and poor-risk AML. Benjamin J. Djulbegovic, MD, PhD Methods Systematic review and meta-analysis of prospective trials evaluating allo- Martha Wadleigh, MD geneic SCT vs nonallogeneic SCT therapies for AML in CR1. The search used the com- Daniel J. DeAngelo, MD, PhD bined search terms allogeneic; acut* and leukem*/leukaem*/leucem*/leucaem*/ Richard M. Stone, MD aml; myelo* or nonlympho* in the PubMed, Embase, and Cochrane Registry of Controlled Trials databases in March 2009. The search identified 1712 articles. Hisashi Sakamaki, MD, PhD Study Selection Prospective trials

Journal

JAMA – American Medical Association

Published: Jun 10, 2009

There are no references for this article.